<DOC>
	<DOCNO>NCT00411281</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine , work different way stop growth abnormal cell , either kill cell stop divide . Giving low-doses cytarabine may effective treatment Down syndrome transient myeloproliferative disorder . Sometimes disease may need treatment progress . In case , observation may sufficient . PURPOSE : This phase III trial study low-dose cytarabine see well work treat infant Down syndrome transient myeloproliferative disorder .</brief_summary>
	<brief_title>Low-Dose Cytarabine Treating Infants With Down Syndrome Transient Myeloproliferative Disorder</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether low-dose cytarabine improve event-free survival ( EFS ) rate infants high-risk transient myeloproliferative disorder ( TMD ) , use high-risk TMD patient clinical trial COG-A2971 historic comparison , infants intermediate-risk TMD , use intermediate-risk TMD patient clinical trial COG-A2971 historic comparison . - Maintain current high overall EFS rate low-risk TMD patient . Secondary - Assess toxicity regimen patient . OUTLINE : This nonrandomized , multicenter , crossover study . Patients stratify accord disease risk ( high intermediate v low ) . - Group I ( patient high- intermediate-risk transient myeloproliferative disorder [ TMD ] ) : Patients receive low-dose cytarabine subcutaneously twice daily day 1-7 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Patients achieve stable disease complete hepatic clinical remission undergo observation . - Group II ( patient low-risk TMD ) : Patients observe . If symptoms intermediate- high-risk disease develop , patient may crossover group I . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 180 patient accrue study .</detailed_description>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemoid Reaction</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis transient myeloproliferative disorder ( TMD ) Diagnosis Down syndrome Down syndrome mosaicism ( confirm karyotype analysis within past 3 week ) AND 1 follow : Nonerythroid nonlymphoid blast ( amount ) peripheral blood verification second sample Trisomy 21positive leukemic blast document biopsy organ ( include &gt; 5 % nonerythroid/nonlymphoid blast document bone marrow aspirate biopsy ) Immunophenotype characterization require High , intermediate , lowrisk TMD , define follow : Highrisk TMD , meet 1 follow criterion : Lifethreatening cardiorespiratory compromise due complication TMD ( e.g. , organomegaly effusion ) Lifethreatening cardiorespiratory compromise define cardiovascular grade 4 edema , grade 4 pericardial effusion , grade 4 pleural effusion Hyperleukocytosis , define WBC &gt; 100,000/mm³ Any degree hepatomegaly ( palpable physical exam ) combine lifethreatening hepatic dysfunction Lifethreatening hepatic dysfunction define grade 4 disseminate intravascular coagulation , grade 4 ascites , grade 4 bilirubin ( &gt; 10.0 time upper limit normal [ ULN ] ) , grade 4 AST ALT ( &gt; 20.0 time ULN ) Intermediaterisk TMD , meet follow criterion : Hepatomegaly ( palpable physical exam ) combine non lifethreatening hepatic dysfunction ( i.e. , grade 13 hepatic dysfunction [ AST ALT ≤ 2.5 time ULN ] and/or total direct bilirubin ≤ 1.5 time ULN ) No evidence lifethreatening cardiovascular , respiratory , hepatic compromise due complication TMD Lowrisk TMD , meet follow criterion : No palpable hepatomegaly physical exam OR hepatomegaly present without hepatic dysfunction ( i.e. , grade 0 hepatic dysfunction ) No evidence lifethreatening cardiovascular , respiratory , hepatic compromise due complication TMD PATIENT CHARACTERISTICS : See Disease Characteristics No biliary atresia hepatic ultrasound patient bilirubin 3.010.0 time ULN PRIOR CONCURRENT THERAPY : No prior antileukemic therapy ( except leukapheresis exchange transfusion )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>acute myeloid leukemia/transient myeloproliferative disorder</keyword>
</DOC>